PharmExec articleshttps://www.pharmexec.com/newsPharmExec articles© 2026 MJH Life Sciences™ and PharmExec. All rights reserved.Sun, 15 Nov 2026 05:13:33 +00005en-us14447https://www.pharmexec.com/newshttps://www.pharmexec.com/logo.webphttps://www.pharmexec.com/view/daily-fda-shelves-cnpv-programhttps://www.pharmexec.com/view/daily-fda-shelves-cnpv-program<![CDATA[FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.]]>Fri, 13 Nov 2026 18:01:12 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-shelves-commissioner-national-priority-voucher-program-reporthttps://www.pharmexec.com/view/fda-shelves-commissioner-national-priority-voucher-program-report<![CDATA[FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.]]>Fri, 13 Nov 2026 15:45:29 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/eli-lilly-breaks-ground-3-billion-pennsylvania-manufacturing-sitehttps://www.pharmexec.com/view/eli-lilly-breaks-ground-3-billion-pennsylvania-manufacturing-site<![CDATA[Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide. ]]>Fri, 13 Nov 2026 14:39:09 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/when-small-protocol-decisions-become-enrollment-or-retention-barriershttps://www.pharmexec.com/view/when-small-protocol-decisions-become-enrollment-or-retention-barriers<![CDATA[Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.]]>Fri, 13 Nov 2026 11:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-moderna-outlines-growth-plan-2026-analyst-dayhttps://www.pharmexec.com/view/daily-moderna-outlines-growth-plan-2026-analyst-day<![CDATA[Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.]]>Thu, 12 Nov 2026 19:33:26 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/moderna-oncology-driven-growth-plan-2026-analyst-dayhttps://www.pharmexec.com/view/moderna-oncology-driven-growth-plan-2026-analyst-day<![CDATA[Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.]]>Thu, 12 Nov 2026 15:10:22 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/pfizer-blackstone-sign-co-funding-deal-berobenatidehttps://www.pharmexec.com/view/pfizer-blackstone-sign-co-funding-deal-berobenatide<![CDATA[Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide. ]]>Thu, 12 Nov 2026 14:35:05 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/patients-use-ai-impact-how-sponsors-communicate-with-themhttps://www.pharmexec.com/view/patients-use-ai-impact-how-sponsors-communicate-with-them<![CDATA[With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.]]>Thu, 12 Nov 2026 11:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-fda-approves-pimjetmihttps://www.pharmexec.com/view/daily-fda-approves-pimjetmi<![CDATA[FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.]]>Wed, 11 Nov 2026 19:51:28 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-approves-pimjetmi-patients-tenosynovial-giant-cell-tumorhttps://www.pharmexec.com/view/fda-approves-pimjetmi-patients-tenosynovial-giant-cell-tumor<![CDATA[FDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors. ]]>Wed, 11 Nov 2026 14:51:22 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/when-patient-input-should-be-collected-clinical-research-processhttps://www.pharmexec.com/view/when-patient-input-should-be-collected-clinical-research-process<![CDATA[AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.]]>Wed, 11 Nov 2026 11:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-fda-requires-safety-label-update-glp1-receptor-agonisthttps://www.pharmexec.com/view/daily-fda-requires-safety-label-update-glp1-receptor-agonist<![CDATA[FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.]]>Tue, 10 Nov 2026 19:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/astrazeneca-acquires-omniose-bioconjugation-platformhttps://www.pharmexec.com/view/astrazeneca-acquires-omniose-bioconjugation-platform<![CDATA[AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs. ]]>Tue, 10 Nov 2026 16:06:01 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/building-connected-ai-ecosystems-not-standalone-toolshttps://www.pharmexec.com/view/building-connected-ai-ecosystems-not-standalone-tools<![CDATA[Experts consider what happens when artificial intelligence (A) tools multiply faster than organizations can connect them.]]>Tue, 10 Nov 2026 15:25:57 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/where-ai-is-having-the-most-impact-and-where-gaps-remainhttps://www.pharmexec.com/view/where-ai-is-having-the-most-impact-and-where-gaps-remain<![CDATA[Zoë Lazarre, Claudia Ciciliano, and Shankar Narayanan assess where artificial intelligence (AI) is already proving its value in pharma commercialization and where to go next.]]>Tue, 10 Nov 2026 15:24:09 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-requests-safety-label-warning-glp-1-receptor-agonist-risk-naionhttps://www.pharmexec.com/view/fda-requests-safety-label-warning-glp-1-receptor-agonist-risk-naion<![CDATA[FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION. ]]>Tue, 10 Nov 2026 15:18:15 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/why-healthcare-requires-a-different-approach-to-aihttps://www.pharmexec.com/view/why-healthcare-requires-a-different-approach-to-ai<![CDATA[A group of experts explore the advantages of purpose-built artificial intelligence (AI) for healthcare over generic models.]]>Tue, 10 Nov 2026 15:13:07 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-approves-asundexian-for-secondary-stroke-risk-reductionhttps://www.pharmexec.com/view/fda-approves-asundexian-for-secondary-stroke-risk-reduction<![CDATA[FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. ]]>Tue, 10 Nov 2026 14:24:12 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/ai-strengthen-clinical-research-patient-input-importanthttps://www.pharmexec.com/view/ai-strengthen-clinical-research-patient-input-important<![CDATA[AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.]]>Tue, 10 Nov 2026 11:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/adjusting-tumor-mutations-brian-corgiathttps://www.pharmexec.com/view/adjusting-tumor-mutations-brian-corgiat<![CDATA[Ignite Proteomics’ senior clinical research scientist discusses how flaws in testing tumors may lead to some patients not receiving the correct treatment.]]>Tue, 10 Nov 2026 11:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-argenx-acquires-unnatural-products-inc-https://www.pharmexec.com/view/daily-argenx-acquires-unnatural-products-inc-<![CDATA[argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.]]>Mon, 09 Nov 2026 20:00:12 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/single-partner-platforms-enhancing-prescription-journey-manufacturershttps://www.pharmexec.com/view/single-partner-platforms-enhancing-prescription-journey-manufacturers<![CDATA[Single-partner platforms can unify manufacturers, prescribers, and patients to eliminate gaps, cut costs, and boost treatment adherence.]]>Mon, 09 Nov 2026 15:56:20 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/argenx-acquires-unnatural-products-inc-expand-immunology-capabilitieshttps://www.pharmexec.com/view/argenx-acquires-unnatural-products-inc-expand-immunology-capabilities<![CDATA[argenx acquires Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. ]]>Mon, 09 Nov 2026 14:25:20 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/effective-methods-accurately-measuring-tumorshttps://www.pharmexec.com/view/effective-methods-accurately-measuring-tumors<![CDATA[Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond what IHC alone reveals.]]>Mon, 09 Nov 2026 11:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/closing-thoughtshttps://www.pharmexec.com/view/closing-thoughts<![CDATA[Pharma leaders on embracing nonlinear careers, leading inclusively, and preserving a distinct voice as AI-generated content becomes the norm.]]>Fri, 06 Nov 2026 20:55:47 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/advice-for-your-younger-selfhttps://www.pharmexec.com/view/advice-for-your-younger-self<![CDATA[Pharma leaders on building networks, asking for stretch opportunities, and approaching AI and remote work with curiosity and confidence.]]>Fri, 06 Nov 2026 20:55:17 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/maintaining-principles-in-an-age-of-aihttps://www.pharmexec.com/view/maintaining-principles-in-an-age-of-ai<![CDATA[Pharma leaders on why AI safety must be designed in from the start—and why human oversight is non-negotiable when patients are affected.]]>Fri, 06 Nov 2026 20:54:26 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/the-relationship-between-setting-a-high-bar-and-building-good-culturehttps://www.pharmexec.com/view/the-relationship-between-setting-a-high-bar-and-building-good-culture<![CDATA[Pharma leaders on building cultures where high performance and human connection coexist—and how shared mission drives progress in complex disease.]]>Fri, 06 Nov 2026 20:53:15 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/maintaining-the-human-side-of-leadershiphttps://www.pharmexec.com/view/maintaining-the-human-side-of-leadership<![CDATA[Pharma leaders on why shared purpose and authentic human connection remain the foundation of effective leadership as digital tools advance.]]>Fri, 06 Nov 2026 20:52:16 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/building-an-organization-that-can-absorb-the-pace-of-changehttps://www.pharmexec.com/view/building-an-organization-that-can-absorb-the-pace-of-change<![CDATA[Pharma leaders on redesigning workflows for agility—and how AI is compressing timelines and reshaping roles across tech, marketing, and MLR.]]>Fri, 06 Nov 2026 20:51:06 GMTPharmExecusPharmExec Articles